INVESTOR RIGHTS AGREEMENT dated as of December 27, 2019 by and among Urovant Sciences Ltd., Sumitovant Biopharma Ltd. and Sumitomo Dainippon Pharma Co., Ltd.Investor Rights Agreement • December 30th, 2019 • Urovant Sciences Ltd. • Pharmaceutical preparations • New York
THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of December 27, 2019 (the “Effective Time”), by and among Urovant Sciences Ltd., an exempted limited company incorporated under the laws of Bermuda (the “Company”), Sumitovant Biopharma Ltd., a Bermuda exempted company limited by shares (“Sumitovant Bio”), and Sumitomo Dainippon Pharma Co., Ltd., a company organized under the laws of Japan (“Sumitomo”).
LOAN AGREEMENTLoan Agreement • December 30th, 2019 • Urovant Sciences Ltd. • Pharmaceutical preparations • New York
This Loan Agreement, dated as of December 27, 2019 (this “Agreement”), is between Sumitomo Dainippon Pharma Co., Ltd., a company (Kabushiki Kaisha) incorporated under the laws of Japan (the “Lender”), and Urovant Sciences Ltd., an exempted company limited by shares and organized under the laws of Bermuda (the “Borrower” and, together with the Lender, the “Parties” and each, a “Party”).
